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ABSTRACT 
 
Background: The renin-angiotensin system has an important role in hepatic 
inflammation and fibrosis. Renin-angiotensin system blockade by angiotensin-
converting enzyme (ACE) inhibitors provides some protective effects against hepatic 
fibrogenesis. Captopril as an ACE inhibitor can decrease inflammatory mediators and 
attenuate hepatic fibrosis in the livers of bile duct ligated (BDL) rats. Objective: The 
present study was conducted to investigate the effects of captopril on cytokine 
production in hepatic fibrosis induced by a bile duct ligation model in rats. Methods: 
Male rats were divided into four groups including; control, sham operated, BDL, and 
BDL plus captopril (10 mg/kg/day, orally). After 28 days of treatment, the livers were 
removed for cytokine analysis. Hepatic interleukin (IL)-10 and tumor necrosis factor 
(TNF)-α levels were measured. Results: Captopril treatment decreased the hepatic 
content of the proinflammatory cytokine TNF-α and increased the anti-inflammatory 
cytokine IL-10. Conclusion: the present study suggests that the protective effect of 
captopril on hepatic fibrosis is likely to be mediated by cytokine production. 
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INTRODUCTION 
 
Angiotensin II plays an important role in liver inflammation and fibrosis. It mediates the 
expression of proinflammatory cytokines and the infiltration of inflammatory cells (1). 
These inflammatory responses occur during the course of hepatic fibrosis (2).        
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Renin-angiotensin system blockade, either by ACE inhibition or angiotensin receptor    
1 (AT1) blockade, has protective effects against the inflammatory response in liver 
fibrogenesis (1). Anti-inflammatory effects of certain ACE inhibitors have been shown 
both in vitro and in vivo. It has been demonstrated that captopril inhibits 
lipopolysaccharide (LPS)-induced production of proinflammatory cytokines such as 
TNF and IL-1β (3). Angiotensin-converting enzyme inhibitors improve hepatic steatosis 
by reducing TNF-α and IL-6 levels in the circulation and the liver (4). Interleukin-10 is 
a potent anti-inflammatory cytokine. It has been demonstrated that IL-10, as an 
immunosuppressive mediator, has a protective effect in some hepatic diseases (5). IL-10 
treatment of patients with chronic hepatitis C reduces hepatic inflammation and fibrosis. 
IL-10 inhibits the production of TNF-α, nuclear factor kB and superoxide anions (6).  
It has been reported that captopril inhibits the progression of hepatic fibrosis induced by 
CCl4 in rats (7). In our previous study, we demonstrated that angiotensin blockade with 
captopril leads to the inhibition of hepatic fibrosis in BDL cirrhotic rat model (8). 
Progression of liver fibrosis during chronic inflammation may be stimulated by the 
production of proinflammatory cytokines that ultimately leads to cell death. The 
purpose of this study was to investigate the effects of captopril, an ACE inhibitor, on 
cytokine production in hepatic fibrosis induced in rat by bile duct ligation. 
 
 
MATERIAL AND METHODS 
 
Animals: Male Albino Wistar rats, weighing 150–200 g were obtained from the 
department of pharmacology, Tehran University of Medical Sciences, Tehran, Iran. 
Every 4 animals were housed in a cage under a 12–12 h light–dark cycle at 22-25°C. 
They were allowed to have free access to ad libitum food and tap water throughout the 
4-week experiment. All experiments were carried out in accordance with institutional 
guidelines for laboratory animal care and use. 
Groups and training protocol: Biliary hepatic fibrosis was induced by common bile 
duct ligation (BDL). Rats were anesthetized with ketamine and xylazine. After midline 
abdominal incision, the common bile duct was doubly ligated with a silk thread. Sham 
operated animals underwent an identical procedure and manipulation of the common 
bile duct without ligation. Four weeks after operation, BDL rats showed signs of liver 
failure, ascites and jaundice. Rats were divided into four experimental groups           
(n=4 in each group) as follows: (1) Control group did not undergo any operation or 
treatment; (2) Sham operated group; (3) BDL group without treatment and (4) BDL plus 
captopril (10 mg/kg/day, orally for 28 days) starting on the first day after BDL 
operation (8). On day 28 rats were euthanized and livers were removed for cytokine 
analysis. 
Cytokine measurement: Liver tissue samples were removed from rats and snap frozen 
in liquid nitrogen. The samples (100mg) were homogenized in 800μl Tris–HCl buffer. 
All homogenized samples were centrifuged at 16,000g for 30min at 4 °C and the 
supernatants were taken and stored at −80 °C (9). The supernatant samples were used 
for the measurement of the cytokine concentrations. Hepatic IL-10 and TNF-α levels 
were measured by using specific ELISA kits (Bender MedSystems GmbH) and the 
results were expressed as pg cytokine/mg wet tissue. 
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Statistical analysis: Data are presented as means ± SEM. Statistical analysis was 
performed using one way ANOVA followed by TUKEY post-hoc test. P < 0.05 was 
considered significant. 
 
 
RESULTS AND DISCUSSION 
 
To evaluate the mechanism of the protective effects of captopril in hepatic fibrosis, we 
measured the levels of TNF-α and IL-10 in supernatants of liver tissues from each study 
group. As shown in figure 1A, bile duct ligation caused remarkable elevation               
(p < 0.001) in the hepatic level of TNF-α as compared with those of the control and the 
sham operated groups. Treatment of rats with captopril reduced BDL-induced 
production of TNF-α compared with the BDL group (p < 0.001). There was no 
significant difference among the control, sham and captopril plus BDL groups. Figure 
1B shows that IL-10 cytokine levels tend to decrease in BDL rats. However, the 
decreasing effect of BDL on hepatic level of IL-10 was not statistically significant when 
compared with the control and the sham operated groups. Administration of captopril 
produced a significant increase (p < 0.05) in the hepatic level of IL-10 compared with 
the BDL group. No significant difference was observed between captopril-treated and 
sham operated groups in this study. 
 
 
Figure 1.  Effect of captopril (10 mg/kg/day) on hepatic levels of TNF-α and IL-10 in four 
experimental groups. Captopril prevented the BDL-induced increase in TNF-α (A), while 
captopril treatment increased the level of IL-10 (B). Data are expressed as mean ± SEM. *P < 
0.001 compared with the sham group; **P < 0.001 compared with BDL group. §P < 0.05 
compared with BDL group. 
 
 
Liver fibrogenesis occurs as a result of hepatic cell injury which leads to recruitment of 
inflammatory cells, followed by the release of cytokines (5). Several reports suggest 
that angiotensin II plays an important role in hepatic fibrosis by inducing the expression 
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of potent cytokines (10,11). Cytokines have an important function in the development 
of hepatic inflammation and fibrosis (2). There is an imbalance between                     
anti-inflammatory and proinflammatory cytokines during liver fibrosis. It has been 
demonstrated that hepatic concentration of TNF-α increases following BDL in mice (1). 
Chronic BDL significantly augments plasma and hepatic levels of proinflammatory 
cytokines such as TNF-α and IL-1β (12). Captopril has a potent inhibitory effect on the 
LPS-induced production of TNF in vitro (13). In another study it is shown that 
pretreatment with captopril inhibits the expression of TNF-α in rabbits (14).  
Some studies have suggested a protective role for the anti-inflammatory cytokine,      
IL-10, on hepatic fibrogenesis. IL-10 inhibits the synthesis of proinflammatory and 
profibrogenic cytokines including TNF-α, IL-6 and TGF-β (2,15). IL-10 decreases the 
levels of some transmitters such as endothelin, angiotensin II and prostacyclin. These 
transmitters have a significant role in rat hepatic fibrosis induced by CCl4 (6). It has 
been shown that IL-10 decreases the damage and the inflammation in a rat model of 
hepatic ischemia and reperfusion (16). The ACE inhibitors enalapril and captopril 
increase IL-10 production by splenocytes in mice (17).  
In our previous study we showed that captopril increases liver glutathione (GSH) 
content, diminishes lipid peroxidation and the hepatic content of hydroxyproline, and 
reduces hepatic inflammation (8). Our present study shows that captopril treatment is 
able to reduce BDL-induced production of the proinflammatory cytokine, TNF-α. This 
observation is important, because TNF-α plays a major role in the development of 
hepatic fibrosis. In addition, we demonstrated that captopril treatment increases the 
hepatic content of IL-10 in BDL rats. Interleukin-10 is an anti-inflammatory cytokine 
and has an important role in the prevention of hepatic inflammation and fibrosis. 
Altogether, the results of current study suggest that the protective effect of captopril in 
hepatic fibrosis is likely to be mediated by cytokine production. 
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